6-(pyridin-3-yl)-3H-quinazolin-4-one | 206191-05-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 6-(pyridin-3-yl)-3H-quinazolin-4-one
• 英文别名: 6-Pyridin-3-yl-3H-quinazolin-4-one；6-pyridin-3-yl-3H-quinazolin-4-one
• CAS: 206191-05-1
• 化学式: C₁₃H₉N₃O
• 分子量: 223.234
• InChiKey: RYEYAUKLIJXVNQ-UHFFFAOYSA-N

物化性质

• 沸点：
  477.0±47.0 °C(Predicted)
• 密度：
  1.33±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-(pyridin-3-yl)-3H-quinazolin-4-one 在 N,N-二甲基苯胺 、 三氯氧磷 作用下， 以 甲苯 为溶剂， 反应 1.0h， 生成 4-chloro-6-(pyridin-3-yl)quinazoline
  参考文献：
  名称：

  Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk)

  摘要：

  Continued examination of substituted 6-arylquinazolin-4-amines as Clk4 inhibitors resulted in selective inhibitors of Clk1, Clk4, Dyrk1A and Dyrk1B. Several of the most potent inhibitors were validated as being highly selective within a comprehensive kinome scan. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2011.02.114
• 作为产物：
  描述：

  6-溴-4-羟基喹唑啉 、 3-吡啶硼酸 在 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 乙二醇二甲醚 、 水 为溶剂， 反应 1.0h， 生成 6-(pyridin-3-yl)-3H-quinazolin-4-one
  参考文献：
  名称：

  Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk)

  摘要：

  Continued examination of substituted 6-arylquinazolin-4-amines as Clk4 inhibitors resulted in selective inhibitors of Clk1, Clk4, Dyrk1A and Dyrk1B. Several of the most potent inhibitors were validated as being highly selective within a comprehensive kinome scan. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2011.02.114

文献信息

• 4-aminoquinazolone derivatives
  申请人：Pfizer Inc

  公开号：US06225318B1

  公开（公告）日：2001-05-01

  This invention relates to certain 4-aminoquinazoline derivatives of the formula and their pharmaceutically acceptable salts wherein R1, Q1, m, n, and Z are defined as in the specification. The compounds of formula I and pharmaceutically acceptable salts are useful for the treatment of hyperproliferative disorders and conditions in mammals.

  这项发明涉及某些4-氨基喹唑啉衍生物及其药用可接受的盐，其化学式为，其中R1、Q1、m、n和Z的定义如规范中所述。化合物I的药用可接受的盐对于哺乳动物的治疗过度增殖性疾病和症状是有用的。
• 4-Aminoquinazoline derivatives
  申请人：PFIZER INC.

  公开号：EP0837063A1

  公开（公告）日：1998-04-22

  This invention relates to certain 4-aminoquinazoline derivatives of the formula and their pharmaceutically acceptable salts wherein R1, Q1, m, n, and Z are defined as in the specification. The compounds of formula I and pharmaceutically acceptable salts are useful for the treatment of hyperproliferative disorders and conditions in mammals.

  本发明涉及某些 4-氨基喹唑啉衍生物，其式为 及其药学上可接受的盐，其中 R1、Q1、m、n 和 Z 的定义如说明书所述。式 I 的化合物及其药学上可接受的盐类可用于治疗哺乳动物的过度增殖性疾病和病症。
• US6225318B1
  申请人：——

  公开号：US6225318B1

  公开（公告）日：2001-05-01
• Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk)
  作者：Andrew S. Rosenthal、Cordelle Tanega、Min Shen、Bryan T. Mott、James M. Bougie、Dac-Trung Nguyen、Tom Misteli、Douglas S. Auld、David J. Maloney、Craig J. Thomas

  DOI：10.1016/j.bmcl.2011.02.114

  日期：2011.5

  Continued examination of substituted 6-arylquinazolin-4-amines as Clk4 inhibitors resulted in selective inhibitors of Clk1, Clk4, Dyrk1A and Dyrk1B. Several of the most potent inhibitors were validated as being highly selective within a comprehensive kinome scan. Published by Elsevier Ltd.